Your session is about to expire
← Back to Search
Photodynamic Therapy for Prostate Cancer
Study Summary
This trial is testing a new cancer treatment that uses light to kill cancer cells. They are testing to see if it is safe and what the best dose is.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My prostate is smaller than 50 cm3 as measured by ultrasound.I currently have an infection.My liver tests are within normal limits.I am mentally capable of understanding and consenting to participate in the trial.My tumor is growing into a major blood vessel near the treatment area.I am currently on or planning to start hormone therapy.I am fully active or restricted in physically strenuous activity but can do light work.I cannot have surgery or curative radiotherapy for my condition.My treatment area is smaller than 50 cubic centimeters.I have had severe or long-lasting inflammation of the rectum from radiation.I am a man over 18 who had radiation for prostate cancer and now have a confirmed local recurrence.I have undergone seed implantation brachytherapy.I cannot have an MRI due to implants, severe kidney issues, or past reactions.My cancer is advanced or has spread to other parts of my body.My kidney function is good, with creatinine ≤ 1.5 mg/dl.My initial prostate cancer diagnosis had a high severity score.I have a condition that worsens with light exposure.I cannot take drugs that increase sensitivity to light.I had surgery less than a week ago, not counting minor procedures.I am currently being treated with a drug that increases sensitivity to light.
- Group 1: PDT and verteporfin dose finding
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What are the key aims of this medical experiment?
"This clinical trial will last for 6 months and measure adverse events related to the protocol therapy, utilizing CTCAE version 4.0 as a metric. Secondary outcomes include the number of patients with localized tumour (assessed via MRI), extra-prostatic or distant disease (assessed by PSMA PET) and any damage done to periprostate tissues due to PDT which can be evaluated through contrast-enhanced/non-contrast enhanced MRI scanning."
How many volunteers have been recruited for this experiment?
"Affirmative. According to clinicaltrials.gov, this study is accepting applicants from 3 different medical locations and needs 66 participants in total. The trial was initially posted on March 21st 2017 and its details were last updated November 15th 2022."
Can you elucidate any precedent for combining photodynamic therapy and verteporfin to determine dosage?
"Currently, 5 studies regarding PDT and verteporfin dose finding are underway. None of these trials have reached the Phase 3 stage yet. Despite being based in Winston-Salem, North carolina, there are 10 different locations that offer this treatment as part of a clinical trial."
Is this investigation currently enrolling participants?
"Affirmative. Per the clinicaltrials.gov website, this research project is presently recruiting participants. It was first advertised on March 21st 2017 and has been recently updated on November 15th 2022. Sixty-six individuals are being accepted from three separate medical centres."
In what kind of medical scenarios is photodynamic therapy (PDT) and verteporfin dose finding implemented?
"Photodynamic therapy (PDT) combined with verteporfin dose finding has been demonstrated to be effective in managing pathologic myopia, subfoveal choroidal neovascularization (CNV), and age-related macular degeneration (AMD)."
Share this study with friends
Copy Link
Messenger